Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress Read more about Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress
Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015 Read more about Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015
Agios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015 Read more about Agios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015
Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation Read more about Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation
Agios Appoints Maykin Ho, Ph.D., to its Board of Directors Read more about Agios Appoints Maykin Ho, Ph.D., to its Board of Directors
Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency Read more about Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency
Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies Read more about Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies
Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies Read more about Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies
Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia Read more about Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia
Agios to Present Clinical and Preclinical Data at the 20th Congress of the European Hematology Association Read more about Agios to Present Clinical and Preclinical Data at the 20th Congress of the European Hematology Association